Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

68.86 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 288
Open 68.86
Bid (Size) 69.04 (2)
Ask (Size) 69.90 (2)
Prev. Close 68.86
Today's Range 68.86 - 68.86
52wk Range 8.280 - 99.41
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Biotech Stocks to Buy on the Dip: April 2024
With medical innovation being a resilient space, investors can have confidence with these biotech stocks to buy on the dip. 
Via InvestorPlace
3 Millionaire-Maker Biotech Stocks
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential. 
Via The Motley Fool

Performance

YTD
+276.70%
+276.70%
1 Month
-14.81%
-14.81%
3 Month
+220.13%
+220.13%
6 Month
+612.47%
+612.47%
1 Year
+252.23%
+252.23%

More News

Read More
VKTX Stock Earnings: Viking Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO
Via Benzinga
3 Biotech Stocks With Skyrocketing Potential: April 2024
Via InvestorPlace
3 Red-Hot Biotech Rockets Blasting Off in 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Looking At Viking Therapeutics's Recent Unusual Options Activity
Via Benzinga
Market Whales and Their Recent Bets on VKTX Options
Via Benzinga
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Via The Motley Fool
Better Buy: Pfizer vs. Viking Therapeutics
Via The Motley Fool
1 No-Brainer Vanguard Fund to Buy Right Now
Via The Motley Fool
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
Via InvestorPlace
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Via MarketBeat
Viking Therapeutics's Options: A Look at What the Big Money is Thinking
Via Benzinga
Is it Too Late to Buy Viking Therapeutics Stock?
Via The Motley Fool
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
Via InvestorPlace
Viking Therapeutics: Strong Results In Obesity
Via Talk Markets
3 Magnificent Stocks That Could Double or More by 2030
Via The Motley Fool
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027
Via InvestorPlace
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
Via InvestorPlace
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
Via The Motley Fool
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
Via The Motley Fool
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Via MarketBeat
Exposures Product Safety
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.